Darunavir

Overview

Darunavir (TMC114), an orally active next generation HIV protease inhibitor, has a similar antiviral activity against the mutant and the wild-type viruses. Darunavir (TMC114) is potent against laboratory HIV-1 strains and primary clinical isolates (IC 50 = 0.003 μM; IC 90 = 0.009 μM) with minimal cytotoxicity.

Application

Products | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Viral Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > HIV | Products > Signaling Pathways > HIV Protease

Product Information

• Catalog No.: HY-17040
• CAS No.: 206361-99-1
• Molecular Formula: C27H37N3O7S
• Molecular Weight: 547.66
• Purity: 99.91%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution
• Availability: In-stock

Source

Original product source